Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly, extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. Its drug delivery technologies include Micropump, LiquiTime, and Medusa. Its Micropump drug-delivery technology allows for the controlled delivery of small molecule drugs taken orally, which improves dosing compliance, reduces toxicity and improves patient compliance. Its LiquiTime technology allows for development of modified release oral products in a liquid suspension formulation, which makes such formulations particularly well suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of modified-release-injectable dosage formulations of drugs, such as peptides, polypeptides, proteins, and small molecules.